March 5,RocheAndAlnylamJointly AnnouncedZilebesIran Treats HypertensionPhase II KARDIA-2 StudyReached the primary endpoint.This study was a randomized, double-blind, placebo-controlled clinical trial (n=672) that evaluatedZilebesiran(600mg, once every 6 months, subcutaneous injection) as an add-on therapy to standard treatment in adult patients with mild to moderate hypertension: Efficacy and Safety.The primary endpoint of the study is at Month 3.Change in 24h average systolic blood pressure (SBP) assessed by ambulatory blood pressure monitoring (ABPM) compared to baseline.Patients were initially randomized into three different cohorts for an open-label lead-in treatment period of at least 4 weeks, with the treatment drug beingOlmesartan Medoxomil、AmlodipineOrIndapamideAfter the lead-in period, patients were randomly assigned to the Zilebesiran group or the placebo group for a 6-month treatment period.The results show that,ZiMean of patients in the lebesiran groupSystolic blood pressure achieved clinical and statistical significance.A statistically significant reduction, and it hasEncouraging safety and tolerability.Roche stated that the detailed results will be announced at the 2024 American College of Cardiology Annual Scientific Session. In addition,Roche and Alnylam Launch Global Phase II KARDIA-3 StudyAimed to evaluate the efficacy and safety of Zilebesiran in hypertensive patients at high cardiovascular risk whose blood pressure remains uncontrolled despite treatment with two or more antihypertensive medications.Zilebesiran is an RNAi therapeutic developed by Alnylam using its Enhanced Stabilization Chemistry Plus (ESC+) GalNAc conjugate technology, targeting angiotensinogen (AGT), aimed at patients with high unmet needs for hypertension treatment.AGTThe Renin-Angiotensin-Aldosterone System（RAAS）in ChinaApexPrecursor, involved in the blood pressure regulation process。ZilebesiranInhibition in the liverAGTThe synthesis may lead toToAGTProtein PersistenceContinuedReduce, and ultimately lead to havingVasoconstrictionActionBlood VesselAngiotensin II（Ang II）Continued decline。In July 2023, Roche andAlnylam reached a cooperation agreement to obtain the global co-development and commercialization rights of the drug for a total transaction value of $3.11 billion.Hypertension is the leading cause of cardiovascular disease worldwide and a major risk factor for premature death in these patients. Approximately one-third of adults globally suffer from hypertension, and about 10 million people lose their lives each year as a result.As time goes by,Not effectivelyControlled hypertension can lead to cardiovascular diseases, including stroke (ischemic and hemorrhagic), coronary artery disease, heart failure, peripheral artery disease, chronic kidney disease and end-stage renal disease, dementia, and Alzheimer's disease.Given the low adherence to existing treatment regimens and the fact that up to 80% of patients with hypertension still do not have their blood pressure effectively controlled,There are still a large number of unmet medical needs in clinical practice.。Copyright © 2024 PHARMCUBE. All Rights Reserved.
Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article.For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.
Disclaimer: The information in this WeChat article is for general reference only and should not be used directly as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.↑Long press to identify QR code / ScanRegistration is open↑
